Innovating Works

LUNG CANCER EUROPE LUCE

Desconocido
SPACETIME: SPatial Analysis of Cancer Evolution in the Tumour Immune MicroEnvironment LUNG CANCER EUROPE LUCE participó en un HORIZON EUROPE: HORIZON-MISS-2023-CANCER-01 The introduction of immune checkpoint therapy for Non-Small Cell Lung Cancer (NSCLC) has improved clinical outcomes. However, due to primary...
2024-06-03 - 2029-07-31 | Financiado
GUIDE.MRD: GUIding multi-moDal thErapies against MRD by liquid biopsies - GUIDE.MRD LUNG CANCER EUROPE LUCE participó en un HORIZON EUROPE: HORIZON-JU-IHI-2022-01-single-stage Advancing personalized approaches in cancer therapy, aiding identification and adaptation of multi-modal treatment strategies for improved o...
2023-05-17 - 2028-04-30 | Financiado
IDERHA: Integration of heterogeneous Data and Evidence towards Regulatory and HTA Acceptance LUNG CANCER EUROPE LUCE participó en un HORIZON EUROPE: HORIZON-JU-IHI-2022-01-single-stage IDERHA will address the key obstacles to achieving appropriate access, sharing, use and reuse of lung cancer data, and thus enable enhanced...
2023-05-10 - 2028-03-31 | Financiado
I3LUNG: Integrative science, Intelligent data platform for Individualized LUNG cancer care with Immunotherap... LUNG CANCER EUROPE LUCE participó en un HORIZON EUROPE: HORIZON-HLTH-2021-CARE-05 Immunotherapy (IO) is the new standard of care for many patients with advanced Non-Small Cell Lung Cancer (aNSCLC), yet only around 30-50% o...
2022-05-23 - 2027-05-31 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.